nodes	percent_of_prediction	percent_of_DWPC	metapath
Nadolol—ADRB3—Monoamine GPCRs—DRD4—conduct disorder	0.0745	0.0745	CbGpPWpGaD
Nadolol—ADRB3—Amine ligand-binding receptors—DRD4—conduct disorder	0.0626	0.0626	CbGpPWpGaD
Nadolol—ADRB3—Monoamine GPCRs—HTR2A—conduct disorder	0.0486	0.0486	CbGpPWpGaD
Nadolol—ADRB3—G alpha (s) signalling events—CGA—conduct disorder	0.0461	0.0461	CbGpPWpGaD
Nadolol—ADRB1—Monoamine GPCRs—DRD4—conduct disorder	0.0442	0.0442	CbGpPWpGaD
Nadolol—ADRB2—Monoamine GPCRs—DRD4—conduct disorder	0.0433	0.0433	CbGpPWpGaD
Nadolol—ADRB3—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0409	0.0409	CbGpPWpGaD
Nadolol—ADRB1—Melatonin metabolism and effects—MAOA—conduct disorder	0.0392	0.0392	CbGpPWpGaD
Nadolol—ADRB1—Amine ligand-binding receptors—DRD4—conduct disorder	0.0372	0.0372	CbGpPWpGaD
Nadolol—ADRB2—Amine ligand-binding receptors—DRD4—conduct disorder	0.0364	0.0364	CbGpPWpGaD
Nadolol—ADRB1—Monoamine GPCRs—HTR2A—conduct disorder	0.0289	0.0289	CbGpPWpGaD
Nadolol—ADRB2—Monoamine GPCRs—HTR2A—conduct disorder	0.0282	0.0282	CbGpPWpGaD
Nadolol—ADRB1—G alpha (s) signalling events—CGA—conduct disorder	0.0274	0.0274	CbGpPWpGaD
Nadolol—ADRB2—G alpha (s) signalling events—CGA—conduct disorder	0.0268	0.0268	CbGpPWpGaD
Nadolol—ADRB1—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0243	0.0243	CbGpPWpGaD
Nadolol—ADRB2—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0237	0.0237	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.022	0.022	CbGpPWpGaD
Nadolol—ADRB2—GPCRs, Other—DRD4—conduct disorder	0.0192	0.0192	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—CGA—conduct disorder	0.0168	0.0168	CbGpPWpGaD
Nadolol—ADRB3—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.0144	0.0144	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0131	0.0131	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0128	0.0128	CbGpPWpGaD
Nadolol—ADRB2—GPCRs, Other—HTR2A—conduct disorder	0.0125	0.0125	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.0123	0.0123	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CGA—conduct disorder	0.00994	0.00994	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CGA—conduct disorder	0.00973	0.00973	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CGA—conduct disorder	0.00947	0.00947	CbGpPWpGaD
Nadolol—ADRB3—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00938	0.00938	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—DRD4—conduct disorder	0.00938	0.00938	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CGA—conduct disorder	0.0086	0.0086	CbGpPWpGaD
Nadolol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00853	0.00853	CbGpPWpGaD
Nadolol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00835	0.00835	CbGpPWpGaD
Nadolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00804	0.00804	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00731	0.00731	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00715	0.00715	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—HTR2A—conduct disorder	0.00612	0.00612	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CGA—conduct disorder	0.00562	0.00562	CbGpPWpGaD
Nadolol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00557	0.00557	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—DRD4—conduct disorder	0.00557	0.00557	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CGA—conduct disorder	0.0055	0.0055	CbGpPWpGaD
Nadolol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00545	0.00545	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—DRD4—conduct disorder	0.00545	0.00545	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—DRD4—conduct disorder	0.0053	0.0053	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CGA—conduct disorder	0.0051	0.0051	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CGA—conduct disorder	0.00508	0.00508	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CGA—conduct disorder	0.00499	0.00499	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—DRD4—conduct disorder	0.00481	0.00481	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00477	0.00477	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00467	0.00467	CbGpPWpGaD
Nadolol—ABCB1—HIF-1-alpha transcription factor network—EP300—conduct disorder	0.00456	0.00456	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—WASF1—conduct disorder	0.00407	0.00407	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.00375	0.00375	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—HTR2A—conduct disorder	0.00363	0.00363	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—HTR2A—conduct disorder	0.00355	0.00355	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—HTR2A—conduct disorder	0.00346	0.00346	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—DRD4—conduct disorder	0.00315	0.00315	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—HTR2A—conduct disorder	0.00314	0.00314	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—DRD4—conduct disorder	0.00308	0.00308	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CGA—conduct disorder	0.00301	0.00301	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CGA—conduct disorder	0.00295	0.00295	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—DRD4—conduct disorder	0.00286	0.00286	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—DRD4—conduct disorder	0.00284	0.00284	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—DRD4—conduct disorder	0.00279	0.00279	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—WASF1—conduct disorder	0.00242	0.00242	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—WASF1—conduct disorder	0.00236	0.00236	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—HTR2A—conduct disorder	0.00205	0.00205	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—HTR2A—conduct disorder	0.00201	0.00201	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.00195	0.00195	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CGA—conduct disorder	0.00187	0.00187	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—HTR2A—conduct disorder	0.00186	0.00186	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—HTR2A—conduct disorder	0.00186	0.00186	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—HTR2A—conduct disorder	0.00182	0.00182	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—DRD4—conduct disorder	0.00169	0.00169	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—DRD4—conduct disorder	0.00165	0.00165	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—HTR2A—conduct disorder	0.0011	0.0011	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—HTR2A—conduct disorder	0.00108	0.00108	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—EP300—conduct disorder	0.000983	0.000983	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—COMT—conduct disorder	0.000846	0.000846	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—MAOA—conduct disorder	0.00084	0.00084	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—EP300—conduct disorder	0.000583	0.000583	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—EP300—conduct disorder	0.000571	0.000571	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—EP300—conduct disorder	0.000363	0.000363	CbGpPWpGaD
